Pivotal epilepsy program with selective Kv7 ion channel activator, opakalim, with expected topline results in 2H 2026. Phase 2 obesity study with myostatin-activin pathway inhibitor, taldefgrobep alfa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results